Tectonic Therapeutic

GPCR Targeting Drugs

Tectonic Therapeutic is discovering and developing therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs). GPCRs are a large class of proteins found on the surface of cells that act as sensors to various extracellular stimuli and are a common target for approved small molecule drugs. However, antibodies are more specific and have more therapeutic potential if they can be successfully identified for GPCRs. Using their proprietary platform, GEODe, Tectonic is discovering and developing GPCR-targeted biologic medicines that can modify the course of disease. Tectonic’s lead program, TX45, is an Fc-relaxin fusion molecule that is under clinical development for patients with pulmonary hypertension.